Clinical Trial Search

Primary: Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of Treatment — -1.06; -1.19 percentage of glycosylated haemoglobin

Primary: Percentage of ACR Responders Per Treatment at Week 6 — 39; 23; 17; 8 Percentage of ACR responders

Primary: Depression at Baseline — 27.5; 25.2 units on a scale

Primary: The Number of Participants That Experience Grade 2-4 Acute GVHD (Graft Versus Host Disease) by Day 100 — 2 participants

Primary: The Difference in Core Body Temperature in the Two Treatment Groups. — 36.28; 36.25 degree celsius

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.28; -1.07; -1.26 percentage of glycosylated haemoglobin

Primary: Change in Glycosylated Haemoglobin (HbA1c) — -1.24; -1.35 percentage of glycosylated haemoglobin

Primary: Estimation of Number of Cases Where FFR Data Results in a Change in the Management Strategy (Number of Vessel Requiring Treatment and/or PCI vs Medical vs CABG) — 147…

Primary: Number of Patients With Cerebrovascular Events, Cardiovascular Events or Death. — 0; 2; 2; 1 participants

Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 1; 1; 1; 1 participants

Primary: Numeric Pain Rating Scale (NPRS) — 6.09; 6.27; 3.73; 3.82 units on a scale

Primary: Change From Baseline in Systolic Blood Pressure (SBP) at Week 6/Final Visit — 0.366; -0.734 mmHg (millimeter of mercury) — p=0.274

Primary: Blood Counts and Adverse Event Profile After 6 Months of Treatment. — 4; 5; 12 participants

Primary: Neutrophil Redistribution Analysis on Day 4 (Neutrophil Nadir) — 26.7; 26.5; 30.8; 50.4 percentage of total body count

Primary: Numerical Rating Scale — 5; 3 scores on a scale